HIV drug resistance strategy, 2021 update

Übersicht

The emergence of HIV drug resistance can compromise the effectiveness of antiretroviral drugs in reducing HIV incidence and HIV-associated morbidity and mortality.

In 2004, WHO collaborated with HIVResNet, a global network of experts providing technical and strategicadvice to WHO on HIV drug resistance, to develop the first strategy for assessing and preventing HIV drug resistance. The strategy was revised in 2012 and in 2015. This publication provides a further update of the strategy, which takes into account the lessons learned from implementing the HIV drug resistance surveillance, the implementation of the global action plan on HIV drug resistance and the ongoing scale-up of antiretroviral therapy and pre-exposure prophylaxis programmes, including the transition to new regimens.

This publication provides an overview of the core set of WHO-recommended activities at the country level, with the aim of supporting programme planning and budgeting. The core activities on HIV drug resistancerecommended by WHO are:
developing and implementing the national action plan on HIV drug resistance;
monitoring the quality-of-care indicators associated with and predicting HIV drug resistance (also known as early warning indicators of HIV drug resistance); and
implementing HIV drug resistance surveys

This publication also briefly summarizes the purpose and structure of the HIV Drug Resistance LaboratoryNetwork, the WHO HIV drug resistance database and the recommendation on timely dissemination and use of HIV drug resistance survey data at the country level.